Account Manager

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

Organization Structure

Product Portfolio:

• Business Focus:
  • Generics: Their business of Generic Formulations offers more than 200 high-quality generic variants of expensive innovator drugs, at a fraction of the cost, in more than 80 countries around the globe. Generic Formulations, including tablets, capsules, injectables, and topical creams, is the largest part of our business portfolio, making products across the major therapeutic areas of gastrointestinal ailments, cardiovascular disease, pain management, oncology, anti-infective, pediatrics, and dermatology.
  • Over-the-Counter: In addition to prescribed medicines, the firm actively develop appropriate products that are available without a doctor's prescription. These important OTC medications reach a much broader population, for example, in Russia and India, the strong OTC portfolio contains some of the most trusted brands in the industry such as Cetrine, Nise Gel, and Novigan, to name a few.
  • Differentiated Formulations: Today, the patients are looking for more than just safe and effective medicines. They also require information, coaching, and customized support to help them adhere to complex treatment protocols. Their Proprietary Products division aims to fulfill these unmet patient needs.
  • APIs (Active Pharmaceutical Ingredients): With deep technical strengths in the development of complex APIs such as steroids, peptides, complex long-chain synthesis, and oncology, they consistently deliver high-quality APIs in US, Japan, Europe,  Korea, Latin America, and many other emerging markets.
  • Biologics: Dr. Reddy’s Labs constantly strive to bring the most advanced medicines within the reach of millions around the world. The efforts at their Biologics division, working on high-quality global biosimilars for the last fifteen years, are a testament to that commitment since the diseases like cancer or autoimmune disorders require the long term use of Biologics.
  • Custom Pharma Services (CPS): It assists pharmaceutical corporations across the value chain from conception to production, from intermediates and medicine substances (APIs) to prescription products.
• Quality: The company rigorously implemented Quality Management System (QMS) which focuses on continual improvement aimed at optimizing processes and eliminating non-value-adding efforts in production. These efforts are directed towards reducing variability in process and product quality characteristics. To achieve this, they follow a four-step process:
  • Adopt Quality by Design (QbD) strategy in production and distinctly recognize the origins of variability and reduce them on a continuous basis.
  • Be right the first time. Identify and eliminate defects. Improve efficiency.
  • Undertake a “risk-based” approach to manufacturing and mitigate risks wherever they are likely to impact quality.
  • Develop clarity in all areas of operations and establish robust quality culture across the enterprise.
• Therapeutic Focus: Understanding patient and partner need deeply and then developing products to meet those needs is central to their purpose. Over the last three decades, they have transformed the company- from a maker of active ingredients to a global, patient-centric company with a global footprint in over 20 countries. They have successfully developed and marketed a range of products, many of which are leaders in their respective markets. Here are some of the most prominent therapies that they focus on:
  • Oncology: Cancer is a disease that requires specialized treatment and care at every stage, so they have developed a broad range of high-quality cancer care medications. Across the spectrum of cytotoxics, targeted therapies, and supportive care, their range is designed to effectively combat cancer and the side effects associated with the therapy.
  • Gastroenterology: Heartburn is a common symptom of gastroesophageal reflux disease, Dr. Reddy’s has developed a broad portfolio of acid-suppressive medications to address this widely prevalent and debilitating disease.
  • Cardiovascular: Since hypertension is more prevalent due to changing lifestyle and dietary plans, so Dr. Reddy’s has developed a wide and varied portfolio of anti-hypertensive medicines to bring good health to the millions affected by this condition.
  • Anti-Diabetic: Along with hypertension, diabetes is another rapidly growing lifestyle health condition the world over. Dr. Reddy’s has a number of established products like Metformin, Glimepiride, Glicazide and their combinations in its portfolio, to ensure good health to diabetics.
  • Dermatology: Dr. Reddy’s has demonstrated expertise to generate solutions for health conditions such as Psoriasis, Corticosteroid-responsive Dermatoses, Seborrheic Dermatitis, various types of Actinic Keratosis, Rosacea, Warts, Dermatitis, and Acne.
  • Pain Management: Dr. Reddy’s has a number of established products, both generic and branded generic, that address a wide range of pain conditions. Products such as Nise, our brand of Nimesulide, is one of the top 300 brands in the Indian pharmaceutical market, for instance.

Subsidiaries:

Few subsidiaries of Dr. Reddy Labs are given below:

• betapharm Arzneimittel GmbH
• Dr. Reddy's Laboratories SA
• Aurigene Discovery Technologies Limited
• Dr. Reddy’s Laboratories (U.K.) Limited
• Cherokee Pharma, LLC
• Dr. Reddy's Laboratories Canada Inc.
• Promius Pharma LLC
• Cheminor Investments Limited
• Reddy Holding GmbH
• Reddy Antilles N.V.

Mergers and Acquisitions

• Dr. Reddy’s acquired UCB’s selected brands in India, Nepal, Sri Lanka, and the Maldives for Rs 800 crores in January 2018. The acquired UCB portfolio would accelerate the company's presence in the high growth areas of dermatology, respiratory and pediatrics, with market-leading brands, according to the firm.
• In 2006, Dr. Reddy’s Laboratories acquired the fourth-largest German generic drug maker betapharm Arzneimittel GmbH for €480 million. This acquisition was considered to be one of the biggest overseas acquisitions by an Indian pharmaceutical company and was part of Dr. Reddy’s lab strategy to expand its presence in all key pharmaceutical markets.

News and Facts

• In June 2019, the company announced its entrance into a definitive agreement to sell its neurology branded products to Upsher-Smith Laboratories, LLC.
• In June 2019, the firm declared its presence at the Goldman Sachs 40th Annual Global Healthcare Conference.
• In April 2019, Dr. Reddy's Laboratories announced the acquisition of ANDA portfolio. The acquisition is in line with its stated strategy to significantly enhance the portfolio in chosen growth markets.

Corporate Social Responsibility

In pursuing social responsibility at Dr. Reddy’s, it follows the guidelines given below:

• Identify the needs and priorities of the community and implement relevant social programs through a structured Social Engagement Plan.
• Pursue social initiatives that:
  • Empower the community by creating urban and rural livelihoods and in particular enhancing skills and employability;
  • Improve access to high-quality education in schools;
  • Support specific initiatives based on need, relevance, and capability in healthcare and hygiene; and
  • Promote the scientific temper to encourage socially relevant innovation in society.
• Distinguish their programs by a focus on volunteering, thus mobilizing employee potential, passion, and talent
• Partner with likeminded complementary organizations to provide socially relevant solution based on innovation and ingenuity.
• Systematically review and monitor the CSR programs using evaluation tools to measure impact and assimilate feedback.